A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda. A multi-national ...

Gilead Chief Medical Officer Dr. Dietmar Berger. Photo: Courtesy Gilead Sciences Inc. Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug ...

The US regulator has started a priority review of the injectable formulation of HIV-1 capsid inhibitor lenacapavir, which also has breakthrough status, and is due to deliver a decision on the ...

A Prescription Drug User Fee Act target date of June 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application ...

Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor, lenacapavir, as a pre-exposure prophylaxis (PrEP) option.

Please provide your email address to receive an email when new articles are posted on . Lenacapavir is delivered in subcutaneous injections given every 6 months. In two phase 3 trials, it was ...

The funding freeze comes at a critical moment, just as a groundbreaking HIV prevention shot -- lenacapavir (Sunlenca) -- ...

The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...